Rocket Pharmaceuticals' shares rallied ahead of the opening bell after the Food and Drug Administration lifted its clinical hold on the biotechnology company's Phase 2 trial of its RP-A501 treatment ...

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) jumped 23% after the U.S. Food and Drug Administration lifted the ...

The MTA board approved an approximately $2 billion tunnel boring contract for the Second Avenue Subway line expansion in ...

Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a ...

Celldex Therapeutics (CLDX) slipped in premarket trading on Wednesday after releasing results from its Phase 2 study of ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Material from the first Phase 2 test has been sent to a leading global fumed silica manufacturer (under LOI) and to an ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Alto Neuroscience Inc. (NYSE: ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto ...

Phase 1 of Wyelea consisted of construction of roads and utilities. Phase 2 includes additional roads and infrastructure ...

The Polihali Transfer Tunnel, a major component of Phase II of the Lesotho Highlands Water Project, showcases modern tunnelling practices ...